Search

Your search keyword '"Ensell L"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Ensell L" Remove constraint Author: "Ensell L"
31 results on '"Ensell L"'

Search Results

1. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

2. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

3. Body composition and lung cancer-associated cachexia in TRACERx

4. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

5. Genomic–transcriptomic evolution in lung cancer and metastasis

6. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

7. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

8. The evolution of lung cancer and impact of subclonal selection in TRACERx

9. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2

10. SARS-CoV-2 evolution during treatment of chronic infection

11. P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA

12. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)

13. Genomic reconstruction of the SARS-CoV-2 epidemic in England

14. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

15. 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas

18. Genomic reconstruction of the SARS-CoV-2 epidemic in England

19. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

20. Recurrent SARS-CoV-2 mutations in immunodeficient patients

21. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2

22. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

23. The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis

24. Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer

25. Spatial growth rate of emerging SARS-CoV-2 lineages in England, September 2020-December 2021

26. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.

27. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms.

28. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.

29. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.

30. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.

31. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Catalog

Books, media, physical & digital resources